This company listing is no longer active
IPOT Stock Overview
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Isracann Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0 |
| 52 Week High | CA$0 |
| 52 Week Low | CA$0 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Recent updates
Shareholder Returns
| IPOT | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | n/a | 2.7% | 0.5% |
| 1Y | n/a | -10.0% | 20.9% |
Return vs Industry: Insufficient data to determine how IPOT performed against the Canadian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IPOT performed against the Canadian Market.
Price Volatility
| IPOT volatility | |
|---|---|
| IPOT Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.2% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: IPOT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IPOT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Ajay Kaila | www.isracann.com |
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. The company also develops cultivation facilities. It exports its products to Germany.
Isracann Biosciences Inc. Fundamentals Summary
| IPOT fundamental statistics | |
|---|---|
| Market cap | CA$2.65m |
| Earnings (TTM) | -CA$4.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IPOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPOT income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$4.54m |
| Earnings | -CA$4.54m |
Last Reported Earnings
Aug 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did IPOT perform over the long term?
See historical performance and comparison